Full-Time

Quality Test and Release Manager

Updated on 9/11/2026

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Marseille, France

Remote

The posting states the role is based in France or the United Kingdom.

Category
Engineering Management (1)
Required Skills
Microsoft Azure
Agile
Postman
SQL
Quality Assurance (QA)
AWS
JIRA
Jenkins
Confluence
Selenium
DevOps
Linux/Unix

Get referred to Cencora

See people who can refer or advise you

Requirements
  • Significant commercial experience leading quality assurance and functional testing for enterprise systems.
  • Strong knowledge of testing methodologies, frameworks, and test management practices.
  • Proven experience with test and defect management tooling; qTest experience is preferred in the posting.
  • Solid understanding of test data requirements and test environment management.
  • Practical experience with Agile and/or DevOps delivery approaches.
  • Good knowledge of continuous integration and continuous delivery and functional testing methods.
  • Understanding of test-driven development and behavior-driven development concepts and techniques.
  • ISTQB Foundation certification.
  • English and French language skills.
Responsibilities
  • Own and lead functional test management for assigned products, projects, and workstreams.
  • Define test scope, approach, plans, and acceptance-criteria alignment, ensuring requirements are testable.
  • Drive creation, review, and maintenance of test plans, scenarios, scripts, and evidence.
  • Manage end-to-end test execution across teams, including manual and automation-aligned testing.
  • Provide progress, coverage, and quality reporting, including release-readiness input and metrics.
  • Assure the quality of quality-assurance and test artefacts and relevant development artefacts related to releases, fixes, integrations, and project deliverables.
  • Identify risks, issues, assumptions, and dependencies; propose mitigations and escalate appropriately.
  • Contribute to and evolve quality-assurance processes, standards, frameworks, and ways of working; strengthen test efficiency and reusability.
  • Ensure adherence to defect-management processes and drive effective triage, prioritization, and remediation.
  • Coordinate test-data planning, creation and curation, and test-data activities across stakeholders.
  • Ensure data and configuration requirements are identified early during story refinement and considered in continuous integration and continuous delivery pipelines where applicable.
  • Lead user-acceptance-testing management, including stakeholder engagement and coordination.
  • Lead, coach, and mentor quality-assurance analysts and testers; identify training needs and drive capability uplift.
  • Manage capacity planning and allocation of internal, remote, and third-party quality-assurance resources.
  • Collaborate with Product, Delivery, Architecture, Development, and Support teams to embed quality throughout the lifecycle.
  • Demonstrate effective testing practices, improve throughput, promote reuse of test artefacts, and drive continuous improvement of quality-assurance and testing processes.
Desired Qualifications
  • Automation and testing tools such as Selenium, LoadRunner, Postman, and Tricentis Tosca.
  • User-interface and accessibility testing.
  • SQL, Linux/Unix, Jenkins, Jira, and Confluence.
  • Azure and AWS services, XML and JSON, and work with large databases.
  • Quality maturity models such as TMMi, the ISO 9000 series, and risk-based testing models.
  • Disaster recovery, high-availability testing, and backup/restore for infrastructure-oriented initiatives.
  • Additional certifications beyond ISTQB Foundation.

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fiscal 2026 Q3 revenue reached $84.8 billion, and EPS guidance rose to $17.75-$17.95.
  • Cencora completed OneOncology in February 2026, strengthening specialty-pharmacy and oncology economics.
  • A $7 billion revolver and $1 billion buyback show lenders and management backing execution.

What critics are saying

  • Opioid litigation still carries a $4.2 billion accrued liability through 2039.
  • Maryland courts vacated Baltimore's $152 million verdict, but appeals can revive distributor exposure.
  • ASP rule changes and 340B guidance threaten community-oncology margins by 2028, hitting OneOncology.

What makes Cencora unique

  • Cencora pairs drug distribution with OneOncology, deepening specialty-care workflow integration.
  • Its global network spans U.S. Healthcare Solutions and International Healthcare Solutions across 51,000 employees.
  • Nucleus inventory tools and cell-gene therapy enablement embed Cencora inside provider operations.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Company News

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.

MarketScreener
Aug 5th, 2026
Cencora boosts credit facility to $7B, extends maturity to 2031

Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.

Yahoo Finance
Aug 1st, 2026
Cencora Q3 earnings preview: analysts expect $4.37 EPS on $84.89B revenue

Wall Street analysts expect Cencora to report quarterly earnings of $4.37 per share, marking a 9.3% year-over-year increase. Revenues are projected to reach $84.89 billion, up 5.2% from the same quarter last year. Over the past 30 days, the consensus earnings per share estimate has been revised upward by 1.3%. Analysts forecast revenue from Total US Healthcare Solutions at $75 billion, representing 2.9% year-over-year growth. International Healthcare Solutions revenue is expected to remain flat at $7.79 billion. Operating income projections show US Healthcare Solutions at $940.87 million and International Healthcare Solutions at $158.45 million. Cencora shares have risen 5.3% over the past month and hold a Zacks Rank of 2, indicating expected outperformance versus the broader market.